With melanoma is on the rise, research delivers hope

Melanoma, the most dangerous form of skin cancer, is being diagnosed more often than ever before. In the United States, an estimated 112,000 new invasive melanoma cases are expected in 2026. This is an increase of about 10% from last year. But over the past decade, invasive melanoma diagnoses have risen nearly 50%. And this rise is not limited to the US - similar rates are being seen globally.

Though a troubling trend, one reason for the increase could be improved detection technology and awareness. Today newer tools such as dermoscopy, along with patient education of skin cancer signs, and more people going for routine skin checks, are factors leading to the diagnosis of a melanoma earlier on. As with most forms of cancer, early detection plays a crucial role in saving lives.

Who is most affected?

Melanoma affects people of all ages, but certain groups are at higher risk. Rates continue to climb among adults over 50, in both men and women. Younger adults are also at risk: melanoma remains one of the most common cancers in people aged 20–39. This is especially true among young women, who may have used tanning beds or participated in increased sun exposure in an effort to darken their skin for aesthetic purposes. 

And yet UV exposure remains the single greatest preventable risk factor, accounting for roughly 90% of all melanoma diagnoses. UV light exposure from tanning beds has been shown to cause widespread melanoma‑linked DNA damage, significantly increasing lifetime risk. 

Better detection now met with better treatment options

Here’s where the story becomes hopeful: despite rising diagnoses, melanoma death rates have steadily declined, thanks largely to revolutionary advances in immunotherapy. Between 2013 and 2022, melanoma mortality dropped 2-3% per year. In 2025, survival for Stage IV melanoma reached 35-50%, more than doubling historical survival rates of 15-18%.  

This shift is directly tied to the development of checkpoint inhibitor immunotherapies and targeted therapies.  Immunotherapy, which helps the body’s own immune system recognize and attack melanoma cells, is now one of the most powerful tools across the board in cancer medicine. 

Transformative treatments gain traction

In addition to immunotherapy, “tumor‑infiltrating lymphocyte,” or TIL therapy (in which a patient’s own immune cells are harvested, expanded, treated, and reinfused) has shown promising long‑term efficacy. This is particularly for patients whose melanoma has stopped responding to other treatments (including immunotherapies). A recent trial demonstrated a 31% response rate and nearly 20% five‑year survival rate.

Even with groundbreaking therapies, melanoma prevention behaviors remain essential. The skin is the body's largest organ and protecting it is an important act of self‑care. Healthy skin reminders:

• Use sunscreen daily, even when it is cloudy
• Avoid tanning beds 
• Wear protective clothing, hats, and sunglasses outdoors
• Do monthly skin checks, noting new or changing moles
• Get dermatologist screenings, especially if you have risk factors like fair skin, many moles, or family history

Melanoma’s rising incidence is concerning, but it’s also a call to action. With improved detection methods, increasing public awareness, and extraordinary advances in immunotherapy, more people are surviving melanoma than ever before. The science is moving quickly.